Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Natalia Baran"'
Autor:
Natalia Baran, Katie Hurrish, Yongwei Su, Shraddha Patel, Cassandra Ramage, Jenna Carter, Holly Edwards, Steven Buck, Sandra Wiley, Maik Hüttemann, Lisa Polin, Juiwanna Kushner, Sijana Dzinic, Kathryn White, Xun Bao, Jing Li, Jay Yang, Julie Boerner, Zhanjun Hou, Gheath Al-Atrash, Sergej Konoplev, Jonathan Busquets, Stefano Tiziani, Larry Matherly, Jeffrey Taub, Marina Konopleva, Yubin Ge
Venetoclax (VEN), in combination with low dose cytarabine (AraC) or a hypomethylating agent, is FDA approved to treat acute myeloid leukemia (AML) in patients who are over the age of 75 or cannot tolerate standard chemotherapy. Despite high response
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a03d99a8c2a425123fb511654ec9d36e
https://doi.org/10.21203/rs.3.rs-2843025/v1
https://doi.org/10.21203/rs.3.rs-2843025/v1
Autor:
Hiroki Akiyama, Ran Zhao, Lauren Ostermann, Ziyi Li, Natalia Baran, Samar Yazdani, Edward Ayoub, Malcolm Pryor, Yuki Nishida, Po Mak, Vivian Ruvolo, Bing Carter, Michael Andreeff, Jo Ishizawa
Resistance to apoptosis in acute myeloid leukemia (AML) cells causes refractory or relapsed disease, associated with dismal clinical outcomes. Ferroptosis, a mode of non-apoptotic cell death triggered by iron-dependent lipid peroxidation, has been in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ce7719e8ba01bfb23e8616e39b463045
https://doi.org/10.21203/rs.3.rs-2657913/v1
https://doi.org/10.21203/rs.3.rs-2657913/v1
Autor:
Marina Konopleva, Courtney DiNardo, Tushar Bhagat, Natalia Baran, Alessia Lodi, Kapil Saxena, Tianyu Cai, Xiaoping Su, Anna Skwarska, Veronica Guerra, Vinitha Kuruvilla, Sergej Konoplev, Shanisha Gordon-Mitchell, Kith Pradhan, Srinivas Aluri, Meghan Collins, Shannon Sweeney, Jonathan Busquet, Atul Rathore, Qing Deng, Michael Green, Steven Grant, Susan Demo, Gaurav Choudhary, Srabani Sahu, Beamon Agarwal, Mason Spodek, Victor Thiruthuvanathan, Britta Will, Ulrich Steidl, George Tippett, Jan Burger, Gautam Borthakur, Elias Jabbour, Naveen Pemmaraju, Tapan Kadia, Steven Kornblau, Naval Daver, Kiran Naqvi, Nicholas Short, Guillermo Garcia-Manero, Stefano Tiziani, Amit Verma
Malignancies can become reliant on glutamine as an alternative energy source and as a facilitator of aberrant DNA methylation, thus implicating glutaminase (GLS) as a potential therapeutic target. We demonstrate preclinical synergy of telaglenastat (
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0d49b9bc46598eb8d2130f229c871d80
https://doi.org/10.21203/rs.3.rs-2518774/v1
https://doi.org/10.21203/rs.3.rs-2518774/v1
Autor:
Marina Konopleva, Timothy Yap, Naval Daver, Mikhila Mahendra, Jixiang Zhang, Carlos Kamiya-Matsuoka, Funda Meric-Bernstam, Hagop Kantarjian, Farhad Ravandi, Meghan Collins, Maria Di Francesco, Ecaterina Dumbrava, Siqing Fu, Sisi Gao, Jason Gay, Sonal Gera, Jing Han, David Hong, Elias Jabbour, Zhenlin Ju, Daniel Karp, Alessia Lodi, Jennifer Molina, Natalia Baran, Aung Naing, Maro Ohanian, Shubham Pant, Naveen Pemmaraju, Prithviraj Bose, Sarina A. Piha-Paul, Jordi Rodon, Carolina Salguero, Koji Sasaki, Anand Singh, Vivek Subbiah, Apostolia M. Tsimberidou, Quanyun Xu, Musa Yilmaz, Qi Zhang, Christopher Bristow, Meenakshi Bhattacharjee, Stefano Tiziani, Timothy Heffernan, Christopher Vellano, Philip Jones, Cobi Heijnen, Annemieke Kavelaars, Joseph Marszalek
While targeting oxidative phosphorylation (OXPHOS) is a rational anticancer strategy, patient benefit with OXPHOS inhibitors in the clinic has yet to be achieved. Based on promising preclinical data, we advanced IACS-010759, a highly potent and selec
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::bfb0af53495d8d3f266334f26eae66b8
https://doi.org/10.21203/rs.3.rs-1506700/v1
https://doi.org/10.21203/rs.3.rs-1506700/v1